News

With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling

Everyone's portfolio should include a couple of monster stocks. What do I mean by "monster"? I'm talking about companies that have a solid earnings track record and offer bright prospects down the

Everyone's portfolio should include a couple of monster stocks. What do I mean by "monster"? I'm talking about companies that have a solid earnings track record and offer bright prospects down the

Everyone's portfolio should include a couple of monster stocks. What do I mean by "monster"? I'm talking about companies that have a solid earnings track record and offer bright prospects down the

Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for

Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for

Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why. Some commentators are calling for

Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to

Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to

You don't have to settle for puny dividend income. Thousands of stocks offer dividends. Many of them, though, have dividend yields that don't amount to a hill of beans.

What if you could invest in

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

If you are looking for a high-yield dividend stock to boost your income, you might be interested in Altria (NYSE: MO) or Viatris (NASDAQ: VTRS). Both companies offer attractive dividend yields of

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

Buying shares of a generic drug manufacturer like Viatris (NASDAQ: VTRS) isn't the right move for everyone. While most investors would look for such companies to have a long history of bulletproof

When looking for stocks that can make one richer, investors often start with names they know. The problem is that the names they know also tend to be the names that everyone knows, and these stocks

Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year. And that leaves the stock trading a few dollars off its record high. It's not surprising Vertex has advanced. The

Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year. And that leaves the stock trading a few dollars off its record high. It's not surprising Vertex has advanced. The

Vertex Pharmaceuticals (NASDAQ: VRTX) has climbed nearly 20% so far this year. And that leaves the stock trading a few dollars off its record high. It's not surprising Vertex has advanced. The

Shares of Novavax (NASDAQ: NVAX) lost 28% of their value in the first six months of the year, according to data from S&P Global Market Intelligence, extending a downtrend that began in early 2022

Amgen (NASDAQ: AMGN) is a global leader in biotechnology, with a market capitalization of over $121 billion. The company has a proven track record of developing breakthrough therapies for

Amgen (NASDAQ: AMGN) is a global leader in biotechnology, with a market capitalization of over $121 billion. The company has a proven track record of developing breakthrough therapies for

Amgen (NASDAQ: AMGN) is a global leader in biotechnology, with a market capitalization of over $121 billion. The company has a proven track record of developing breakthrough therapies for

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your